Compare · EPRX vs ZOM
EPRX vs ZOM
Side-by-side comparison of Eupraxia Pharmaceuticals Inc. (EPRX) and Zomedica Corp. (ZOM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EPRX and ZOM operate in Pharmaceuticals and Biotechnology (Health Care), so they compete in similar markets.
- ZOM carries a market cap of $284.2M.
- EPRX has hit the wire 7 times in the past 4 weeks while ZOM has been quiet.
- EPRX has more recent analyst coverage (6 ratings vs 1 for ZOM).
- Company
- Eupraxia Pharmaceuticals Inc.
- Zomedica Corp.
- Price
- $7.17-1.51%
- $0.10-3.15%
- Market cap
- -
- $284.2M
- 1M return
- +1.13%
- -
- 1Y return
- +83.61%
- -
- Industry
- Pharmaceuticals and Biotechnology
- Pharmaceuticals and Biotechnology
- Exchange
- NASDAQ
- AMEX
- IPO
- 2017
- News (4w)
- 7
- 0
- Recent ratings
- 6
- 1
Zomedica Corp.
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA, a diagnostic biosensor platform for the detection of thyroid disorders in dogs and cats, and adrenal disorders in dogs. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
Latest EPRX
- SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.
- Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting
- SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.
- Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
- SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.
- SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.
- Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences
- William Blair initiated coverage on Eupraxia Pharmaceuticals
- SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.
- Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
Latest ZOM
- Diality Appoints Peter Donato as Chief Financial Officer
- Zomedica Announces Collaboration with Prime Video as Assisi Loop(R) Products Appear in New Holiday Film Merv
- Zomedica Expands TRUFORMA(R) Diagnostic Menu with Launch of Equine Progesterone Assay
- Zomedica Announces "Friday at Four" Webinar on November 21st Providing Strategic Overview & Third Quarter 2025 Business Review
- Zomedica Achieves ISO 13485 Certification, Underscoring Strengthened Quality Infrastructure and Commercial Potential
- Zomedica Announces Third Quarter 2025 Financial Results: Revenue up 16% to $8.1 Million with 67% Gross Margins and $54 Million in Liquidity to Support Growth
- Zomedica Announces Launch of the Assisi Loop Lounge(R), Scientifically Backed tPEMF(TM) Therapy for Pets
- Zomedica Expands Grovet's Distribution Agreement to Include Zomedica's Diagnostic and Therapeutic Device Products Across the European Union
- Zomedica to Spotlight VETGuardian(R) Zero Touch(TM) Monitor in October "Fourth Friday at Four" Webinar
- Zomedica Expands TRUFORMA(R) Diagnostic Platform with Addition of Feline Use to Cobalamin & Folate Assay